Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OUTFLOW study
2024-516279-34-00Phase 4Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of oxygen in pulmonary hypertension (PH), Coronary Small Vessel Disease (CMD), hypoxia and 1 more (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Cardiac output at 10 minutes after the start of each intervention. Planned start Oct 2024; status: authorised.
02
Drugs
oxygen
03
Conditions
pulmonary hypertension (PH)Coronary Small Vessel Disease (CMD)hypoxiaheart failure (HF)
Beyond the preview
Go deeper on 2024-516279-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516279-34-00.